title: A case of pseudotumor cerebri following glucocorticoid therapy in which warfarin prevented recurrence.
abstract: A patient with nephrotic syndrome developed pseudotumor cerebri following glucocorticoid therapy. Diagnosis of pseudotumor cerebri was based on satisfaction of four criteria proposed by Ahlskog and O'Neill. The symptoms of pseudotumor cerebri disappeared within 10 days. After a three-week interval of remission, relapse occurred. Glycerol and urokinase produced rapid resolution of the symptoms and warfarin prevented further recurrence of pseudotumor cerebri for one year. These results suggest that the pathogenesis of pseudotumor cerebri might be associated with the hypercoagulable state which was induced by glucocorticoid therapy and nephrotic syndrome.
authors.affiliation: Department of Internal Medicine, Municipal Ida Hospital, Kawasaki, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Sakamaki
authors.forename: R
authors.initials: R
authors.lastname: Nakamura
authors.forename: M
authors.initials: M
authors.lastname: Uchida
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: S
authors.initials: S
authors.lastname: Okajima
mesh_terms: D000328:Adult; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D005990:Glycerol / Q000627:therapeutic use; D006261:Headache / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D011559:Pseudotumor Cerebri / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D012008:Recurrence; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D014859:Warfarin; D011239:Prednisolone; D014568:Urokinase-Type Plasminogen Activator; D005990:Glycerol